2'-Fucosyllactose Alleviates Metabolic Hypertension in Mice via Gut Microbiota Modulation and Involvement of the LPS/TLR4 Signaling.

2'-Fucosyllactose (2'-FL) shows promise in ameliorating metabolic disorders. However, the role of 2'-FL in metabolic hypertension (MH) remains unclear. This study aimed to evaluate the effects of 2'-FL on MH and explore its underlying mechanisms. 2'-FL treatment (1000 mg/kg) reduced systolic blood pressure (SBP) by 16.6% and alleviated dyslipidemia, microglial activation, and neuroinflammation in MH mice. 2'-FL markedly increased short-chain fatty acids (SCFAs)-producing beneficial bacteria, e.g.,